NeuroVive’s Board Members and Senior Executives subscribe to shares in the ongoing rights issue

In the ongoing rights issue in NeuroVive, the Board and Senior Executives have undertaken to subscribe for at least 446,176 shares.

The subscription period will continue until 29 April, 2020, and is open to both existing and new investors.

Read more about the rights issue at http://www.neurovive.com/rightsissue2020ld/.

Prospectus (in Swedish), containing full terms and conditions, as well as application forms are available on NeuroVive’s website www.neurovive.com, and on Erik Penser Bank’s website www.penser.se.

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market’s Pink Open market in the US (OTC: NEVPF).

Attachments

NeuroVive’s Board Members and Senior Executives subscribe to shares in the ongoing rights issue